Egfr Targeting
Egfr Targeting - Related Videos
08:52
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
0 Views •
Cited by 7 •
2021
This protocol describes a standardized evaluation of drug sensitivities to targeted signaling inhibitors in NSCLC patient-derived organoid models.
08:12
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
0 Views •
Cited by 4 •
2020
The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR proteins.
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
0 Views •
Cited by 4 •
2017
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
0 Views •
2025
This protocol describes an automated, ISO15189-accredited next-generation sequencing workflow for detecting targetable genomic alterations in non-small cell lung cancer (NSCLC) formalin-fixed paraffin-embedded tissues.
08:35
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
0 Views •
Cited by 28 •
2012
Type B gelatin-based engineered nanovectors system (GENS) was developed for systemic gene delivery and transfection in the treatment of pancreatic cancer. By modification with epidermal growth factor receptor (EGFR) specific peptide on the surface of nanparticles, they could target on EGFR receptor and release plasmid under reducing environment, such as high intracellular glutathione concentrations.
FAQs
The two approaches interrupt EGFR signaling at different points. Therapeutic antibodies can prevent ligand binding or receptor activation, whereas small-molecule tyrosine kinase inhibitors block EGFR phosphorylation inside the signaling process. This distinction matters because the agents engage different functional steps and can be evaluated separately when designing treatment strategies for cancers driven by EGFR activity.
These pathways transmit signals from EGFR to cellular programs that support tumor-cell proliferation and survival. Blocking receptor activity can therefore reduce signaling through both routes rather than affecting only the receptor itself. Their involvement helps explain why EGFR targeting may limit cancer-cell growth and why pathway reactivation can undermine the treatment effect.
Resistance can emerge when secondary mutations alter the target or when downstream signaling becomes active again despite EGFR inhibition. In either case, the original treatment may no longer suppress the signals sustaining tumor-cell growth and survival. These mechanisms provide a rationale for investigating combination treatments and next-generation therapies that address renewed or altered signaling.
EGFR testing supports biomarker-guided decisions by helping identify tumors in which this target may be relevant. Rather than applying the same strategy to every cancer, researchers and clinicians can use test results to inform treatment selection in appropriate cases. This approach is particularly relevant when evaluating selected lung and colorectal tumors for targeted treatment options.
A research workflow can connect EGFR testing with treatment evaluation: investigators first use biomarker information to guide the choice of an EGFR-directed strategy, then assess whether signaling suppression corresponds with reduced tumor-cell proliferation or survival. When resistance appears, studies can examine secondary mutations or pathway reactivation and test combination or next-generation approaches.
EGFR-directed strategies have relevance in selected lung and colorectal tumors, where abnormal receptor activity may contribute to disease behavior. Research evaluates whether blocking that activity can limit tumor-cell proliferation and survival. Studies also examine why responses differ among tumors and how resistance mechanisms may guide improved treatment combinations or newer inhibitors.